This article is the second in a series of two publications on the European Crohn's and Colitis
Organisation [ECCO] evidence-based consensus on the management of Crohn's disease …

Perianal fistulizing Crohn's disease (CD) represents a severe phenotype of CD that is
associated with significant morbidity and reduction in quality of life. Perianal fistulizing CD is …

Perianal fistulizing Crohn's Disease (pCD) affects about 25% of patients with Crohn's
Disease (CD). It remains a difficult entity to manage with a therapeutic ceiling of treatment …

Introduction The first subcutaneous (SC) formulation of infliximab (IFX), CT‑P13 SC, has
been approved in Europe and Australia, including for the treatment of inflammatory bowel …

Abstract Background and Aims Perianal fistulizing Crohn's disease [pfCD] is a disabling
phenotype of Crohn's disease [CD] with suboptimal outcomes. We assessed neutrophil …

Perianal fistulas are a common complication of Crohn's disease (CD) that has, historically,
been challenging to manage. Despite the strong available evidence that anti-tumor necrosis …

Inflammatory bowel disease (IBD) is an incurable disease characterized by remission-
relapse cycles throughout its course. Both Crohn's disease (CD) and ulcerative colitis (UC) …

Crohn's disease (CD) is a chronic inflammatory bowel disease (IBD) that is characterized by
transmural inflammation that can affect any part of the gastrointestinal tract, leading to …

Abstract Crohn's disease (CD), a chronic inflammatory bowel disorder, manifests in various
phenotypes, with fistulizing perianal CD (CD-PAF) being one of its most severe phenotypes …

Background Crohn's disease perianal fistulae (CD-PAF) occur in 25% of patients and are
notoriously challenging to manage. Tumor necrosis factor inhibitors are first line agents …